Eyepoint Historical Balance Sheet

EYPT Stock

USD 7.17 0.48 6.27%

Trend analysis of Eyepoint Pharmaceuticals balance sheet accounts such as Other Current Liabilities of 21.9 M or Total Current Liabilities of 76.4 M provides information on Eyepoint Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Eyepoint Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Eyepoint Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eyepoint Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eyepoint Pharmaceuticals is a good buy for the upcoming year.

Eyepoint Pharmaceuticals Inventory

4.72 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

About Eyepoint Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Eyepoint Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Eyepoint Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Eyepoint Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Eyepoint currently owns. An asset can also be divided into two categories, current and non-current.

Eyepoint Pharmaceuticals Balance Sheet Chart

At this time, Eyepoint Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 4.7 M in 2025, despite the fact that Retained Earnings are likely to grow to (634.5 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Eyepoint Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Eyepoint Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Eyepoint Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eyepoint Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Eyepoint Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Eyepoint Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.At this time, Eyepoint Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 4.7 M in 2025, despite the fact that Retained Earnings are likely to grow to (634.5 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	45.8M	4.9M	5.6M	5.4M
Total Assets	180.4M	355.2M	408.5M	428.9M

Short Long Term Debt Total Total Assets

Eyepoint Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Common Stock Shares Outstanding	Accounts Payable	Other Assets
Total Assets		-0.17	0.9	0.97	0.99	0.94	-0.96	-0.85	0.99	0.11	0.19	0.99	0.18	-0.22	0.38	0.81	0.72	0.97	0.88	0.94	1.0	0.51	-0.18	0.96	0.66	0.18
Short Long Term Debt Total	-0.17		-0.1	-0.24	-0.3	-0.18	0.39	-0.26	-0.28	0.57	0.63	-0.27	0.85	-0.35	0.75	0.26	0.33	-0.03	0.22	-0.24	-0.22	0.43	0.87	-0.02	0.4	0.26
Other Current Liab	0.9	-0.1		0.91	0.86	0.83	-0.83	-0.83	0.88	0.18	0.37	0.88	0.22	-0.26	0.46	0.66	0.76	0.9	0.88	0.83	0.89	0.58	-0.02	0.9	0.75	0.16
Total Current Liabilities	0.97	-0.24	0.91		0.95	0.97	-0.93	-0.83	0.97	0.07	0.15	0.97	0.04	-0.22	0.33	0.77	0.71	0.96	0.87	0.98	0.97	0.51	-0.27	0.94	0.65	-0.02
Total Stockholder Equity	0.99	-0.3	0.86	0.95		0.92	-0.98	-0.77	0.99	-0.01	0.11	1.0	0.07	-0.19	0.23	0.73	0.65	0.94	0.79	0.93	0.99	0.38	-0.29	0.93	0.55	0.19
Property Plant And Equipment Net	0.94	-0.18	0.83	0.97	0.92		-0.89	-0.83	0.94	0.01	0.18	0.94	0.08	-0.17	0.32	0.81	0.75	0.95	0.85	1.0	0.95	0.45	-0.29	0.94	0.64	-0.09
Net Debt	-0.96	0.39	-0.83	-0.93	-0.98	-0.89		0.74	-0.98	0.05	-0.01	-0.97	0.02	0.17	-0.18	-0.68	-0.56	-0.9	-0.73	-0.9	-0.96	-0.34	0.36	-0.88	-0.48	-0.17
Retained Earnings	-0.85	-0.26	-0.83	-0.83	-0.77	-0.83	0.74		-0.8	-0.28	-0.48	-0.81	-0.46	0.52	-0.67	-0.85	-0.84	-0.93	-0.92	-0.8	-0.83	-0.65	-0.19	-0.9	-0.77	-0.21
Cash	0.99	-0.28	0.88	0.97	0.99	0.94	-0.98	-0.8		0.03	0.1	1.0	0.07	-0.19	0.28	0.77	0.65	0.95	0.83	0.95	1.0	0.43	-0.29	0.94	0.6	0.16
Non Current Assets Total	0.11	0.57	0.18	0.07	-0.01	0.01	0.05	-0.28	0.03		0.06	0.01	0.5	-0.21	0.76	0.35	0.13	0.14	0.45	-0.01	0.04	0.85	0.46	0.07	0.63	0.09
Non Currrent Assets Other	0.19	0.63	0.37	0.15	0.11	0.18	-0.01	-0.48	0.1	0.06		0.14	0.76	-0.24	0.53	0.29	0.76	0.3	0.38	0.11	0.18	0.28	0.68	0.41	0.39	0.27
Cash And Short Term Investments	0.99	-0.27	0.88	0.97	1.0	0.94	-0.97	-0.81	1.0	0.01	0.14		0.09	-0.2	0.28	0.76	0.68	0.96	0.83	0.95	1.0	0.42	-0.26	0.95	0.59	0.16
Net Receivables	0.18	0.85	0.22	0.04	0.07	0.08	0.02	-0.46	0.07	0.5	0.76	0.09		-0.16	0.82	0.49	0.59	0.25	0.46	0.02	0.14	0.51	0.83	0.33	0.54	0.48
Common Stock Total Equity	-0.22	-0.35	-0.26	-0.22	-0.19	-0.17	0.17	0.52	-0.19	-0.21	-0.24	-0.2	-0.16		-0.27	-0.16	-0.24	-0.39	-0.29	-0.17	-0.21	-0.27	-0.3	-0.23	-0.25	-0.33
Non Current Liabilities Total	0.38	0.75	0.46	0.33	0.23	0.32	-0.18	-0.67	0.28	0.76	0.53	0.28	0.82	-0.27		0.7	0.6	0.46	0.75	0.27	0.33	0.82	0.64	0.47	0.81	0.26
Inventory	0.81	0.26	0.66	0.77	0.73	0.81	-0.68	-0.85	0.77	0.35	0.29	0.76	0.49	-0.16	0.7		0.71	0.84	0.91	0.78	0.79	0.62	0.11	0.84	0.73	0.14
Other Current Assets	0.72	0.33	0.76	0.71	0.65	0.75	-0.56	-0.84	0.65	0.13	0.76	0.68	0.59	-0.24	0.6	0.71		0.79	0.81	0.71	0.71	0.55	0.3	0.87	0.69	0.08
Other Stockholder Equity	0.97	-0.03	0.9	0.96	0.94	0.95	-0.9	-0.93	0.95	0.14	0.3	0.96	0.25	-0.39	0.46	0.84	0.79		0.91	0.94	0.97	0.54	-0.08	0.97	0.71	0.17
Total Liab	0.88	0.22	0.88	0.87	0.79	0.85	-0.73	-0.92	0.83	0.45	0.38	0.83	0.46	-0.29	0.75	0.91	0.81	0.91		0.83	0.85	0.78	0.15	0.9	0.88	0.13
Property Plant And Equipment Gross	0.94	-0.24	0.83	0.98	0.93	1.0	-0.9	-0.8	0.95	-0.01	0.11	0.95	0.02	-0.17	0.27	0.78	0.71	0.94	0.83		0.95	0.43	-0.35	0.93	0.61	-0.1
Total Current Assets	1.0	-0.22	0.89	0.97	0.99	0.95	-0.96	-0.83	1.0	0.04	0.18	1.0	0.14	-0.21	0.33	0.79	0.71	0.97	0.85	0.95		0.45	-0.22	0.96	0.62	0.17
Intangible Assets	0.51	0.43	0.58	0.51	0.38	0.45	-0.34	-0.65	0.43	0.85	0.28	0.42	0.51	-0.27	0.82	0.62	0.55	0.54	0.78	0.43	0.45		0.35	0.52	0.81	-0.03
Common Stock	-0.18	0.87	-0.02	-0.27	-0.29	-0.29	0.36	-0.19	-0.29	0.46	0.68	-0.26	0.83	-0.3	0.64	0.11	0.3	-0.08	0.15	-0.35	-0.22	0.35		-0.03	0.26	0.41
Common Stock Shares Outstanding	0.96	-0.02	0.9	0.94	0.93	0.94	-0.88	-0.9	0.94	0.07	0.41	0.95	0.33	-0.23	0.47	0.84	0.87	0.97	0.9	0.93	0.96	0.52	-0.03		0.68	0.15
Accounts Payable	0.66	0.4	0.75	0.65	0.55	0.64	-0.48	-0.77	0.6	0.63	0.39	0.59	0.54	-0.25	0.81	0.73	0.69	0.71	0.88	0.61	0.62	0.81	0.26	0.68		0.14
Other Assets	0.18	0.26	0.16	-0.02	0.19	-0.09	-0.17	-0.21	0.16	0.09	0.27	0.16	0.48	-0.33	0.26	0.14	0.08	0.17	0.13	-0.1	0.17	-0.03	0.41	0.15	0.14

Click cells to compare fundamentals

Eyepoint Pharmaceuticals Account Relationship Matchups

Eyepoint Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	91.7M	263.4M	180.4M	355.2M	408.5M	428.9M
Short Long Term Debt Total	46.4M	38.4M	45.8M	4.9M	5.6M	5.4M
Other Current Liab	687K	14.4M	16.4M	18.2M	20.9M	21.9M
Total Current Liabilities	14.9M	23.7M	34.5M	63.3M	72.8M	76.4M
Total Stockholder Equity	18.5M	184.4M	96.4M	266.3M	306.3M	321.6M
Property Plant And Equipment Net	3.2M	2.3M	6.0M	10.2M	11.8M	12.4M
Net Debt	(4.6M)	(140.2M)	(49.9M)	(276.4M)	(248.7M)	(236.3M)
Retained Earnings	(510.7M)	(569.1M)	(671.4M)	(742.1M)	(667.9M)	(634.5M)
Cash	44.9M	178.6M	95.6M	281.3M	323.5M	339.6M
Non Current Assets Total	28.6M	25.6M	7.5M	10.4M	9.3M	8.9M
Cash And Short Term Investments	44.9M	211.6M	144.6M	331.1M	380.7M	399.7M
Net Receivables	9.5M	18.4M	15.5M	805K	925.8K	879.5K
Liabilities And Stockholders Equity	91.7M	263.4M	180.4M	355.2M	408.5M	428.9M
Non Current Liabilities Total	58.3M	55.3M	49.5M	25.6M	29.4M	17.4M
Inventory	5.3M	3.6M	2.9M	3.9M	4.5M	4.7M
Other Current Assets	3.4M	7.9M	18.9M	9.0M	10.4M	10.9M
Other Stockholder Equity	528.4M	752.6M	766.9M	1.0B	1.2B	1.2B
Total Liab	73.2M	79.0M	84.0M	88.9M	102.2M	107.3M
Property Plant And Equipment Gross	3.2M	2.3M	6.0M	12.8M	14.7M	15.5M
Total Current Assets	63.1M	237.7M	172.8M	344.8M	396.5M	416.3M
Intangible Assets	31.4M	27.7M	25.2M	22.7M	20.5M	19.1M
Common Stock	528.4M	752.6M	766.9M	49K	56.4K	53.5K
Common Stock Shares Outstanding	12.8M	28.8M	37.3M	38.9M	44.7M	47.0M
Accounts Payable	4.8M	7.4M	5.9M	6.5M	7.5M	7.9M
Property Plant Equipment	357K	630K	2.3M	1.4M	1.2M	1.3M
Current Deferred Revenue	945K	1.1M	1.2M	38.6M	34.7M	33.0M
Long Term Debt	47.2M	38.0M	36.6M	29.3M	33.7M	35.4M
Short Term Debt	8.4M	782K	11.1M	563K	506.7K	481.4K
Other Liab	3M	18.0M	16.9M	14.2M	16.3M	8.6M
Net Tangible Assets	(19.3M)	(6.7M)	161.6M	96.4M	110.8M	116.4M
Capital Surpluse	472.7M	528.4M	752.6M	766.9M	881.9M	467.0M
Net Invested Capital	56.5M	220.9M	136.2M	266.3M	306.3M	321.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eyepoint Historical Balance Sheet

Eyepoint Pharmaceuticals Inventory

4.72 Million

About Eyepoint Balance Sheet Analysis

Eyepoint Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Eyepoint Pharmaceuticals balance sheet Correlations

Eyepoint Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eyepoint Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Eyepoint Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Cash And Short Term Investments	- 0.97	Net Debt
Total Current Assets	- 0.96	Net Debt
Net Debt	- 0.96	Total Assets
Other Stockholder Equity	- 0.93	Retained Earnings